about
Growth hormone receptor antagonists therapy for acromegaly.Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic PitfallGrowth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.Corticosteroids and pregnancy.Pegvisomant in the treatment of acromegaly.Clinical use of pegvisomant for the treatment of acromegaly.Recent developments in the therapy of acromegaly.Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy.IGF-I measurements in the monitoring of GH therapy.ACROSTUDY: the first 5 years.A consensus on criteria for cure of acromegaly.Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission.Regulation of cortisol bioavailability--effects on hormone measurement and action.The use of mass spectrometry to improve the diagnosis and the management of the HPA axis.The harmonisation of growth hormone measurements: taking the next steps.Evaluation of pituitary function.Current management practices for acromegaly: an international survey.Commentary: Harmonizing growth hormone measurements: learning lessons for the future.Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.Salivary cortisone is a potential biomarker for serum free cortisol.Novel corticosteroid-binding globulin variant that lacks steroid binding activity.Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions.Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH.Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve.Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.Early diagnosis of acromegaly: computers vs clinicians.Long-term experience of pegvisomant therapy as a treatment for acromegaly.Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.
P50
Q33979558-3EA0F970-C1DC-4ADE-9BDE-D52D170F99E5Q34127561-AEC3BAF7-534C-4109-8726-6FF32306B5BDQ34953495-65F26B19-AE75-4CD3-8F08-DD1765FB6557Q35049045-8EC7A1DB-7D76-44FD-A4F8-EB570969256CQ35538340-9660B887-0B5D-4540-8586-2DF003DFEFE3Q36176292-B9459507-7834-4EDA-8D0A-9BE6451AF1E1Q36407309-F8DE476D-5CE3-4178-AC9A-913F05D462EBQ36620601-CA6D0C08-8F72-4BD2-A1FD-2CFB3D56086FQ36780869-6982352B-1719-4947-996C-849298FFD67DQ37580573-AD4297F4-4BB9-499F-9CEE-6550AE66D960Q37735560-7915C140-97A4-4300-9544-AE8B053BDE33Q37913480-BCAE273D-F291-41BA-BA75-96EDC55F1A18Q38034355-9CEFBFE8-F0D5-4AC8-AF8A-ACBD3E8F98F7Q38089640-ACF30A19-5D62-4B70-B509-3E04DF375606Q38186479-B64AFD3E-2ED0-45B1-BDF4-D56CFAF36B62Q38253528-A6E4F0C8-F477-42F7-92B9-8530CC732768Q39818772-63C219AD-BBC0-47E6-A4F4-454B06CCE1C8Q40185994-371324AA-B513-42F7-BFC5-E0248B878231Q40229787-FE9517DD-AD91-4730-B71C-D1C8C4FC91F3Q42171156-E98C4FE6-DADC-4C68-B5A0-22AD30FCF35CQ42452154-A08DC8E2-C98C-483D-9C5A-377AD992861EQ42602272-3BB1A724-90F4-45BE-B764-C300F334B414Q42633725-0122FE5B-ADDB-4EA6-8111-67670A32CE34Q42946258-732BA1CB-44E4-46A8-B002-E76D4DA488AEQ42976964-D4C98AFE-5E91-467E-B0CF-ED632693347EQ43188325-E81E4985-F8AE-425B-A3C6-A099F41C6BAFQ43270748-C0972DB6-EB97-4770-8AC7-B791C8D89AE4Q43666468-6F250AA6-9D9B-4BA5-B9B8-C816568C0287Q43794573-7ACC39D6-CD23-442F-9F05-F449FCBCA2DCQ43816270-8668553E-64AE-4AE8-989C-C1F0D9CEC1D2Q43946926-5D3BCA8A-BFBB-40D9-BE78-FEBF439EBF7BQ43952010-A59B0462-23C7-4D13-AE48-A934A472B659Q44051792-A454ED3F-DAAA-4A8A-9843-CD7516D02E78Q44514155-81695AA5-B45A-4180-B479-1651C33CAB41Q44624482-EA1C04E6-D4D0-41A2-A67E-369B8907586EQ44670604-8BED2375-E216-41A8-A06C-49C1F3CBE1BCQ44740681-3DF6D246-84BB-4937-80E2-48A48933B107Q45066617-AA2998F3-B451-4200-8272-A01FCA8110E5Q45099001-416DEC6A-0A77-4B29-8BCE-DBFCFA04BBF0Q45244353-4FAEEDE2-840D-4535-85D9-99A7C2775C16
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Peter J. Trainer
@ast
Peter J. Trainer
@en
Peter J. Trainer
@es
Peter J. Trainer
@nl
Peter J. Trainer
@sl
type
label
Peter J. Trainer
@ast
Peter J. Trainer
@en
Peter J. Trainer
@es
Peter J. Trainer
@nl
Peter J. Trainer
@sl
altLabel
Peter Trainer
@en
prefLabel
Peter J. Trainer
@ast
Peter J. Trainer
@en
Peter J. Trainer
@es
Peter J. Trainer
@nl
Peter J. Trainer
@sl
P106
P1153
7006819598
P21
P31
P496
0000-0003-0146-3835